29 May, 2026 14:33:45 IST 
Swiss contract development and manufacturing organisation (CDMO) CordenPharma has agreed to acquire AmbioPharm, a peptide API CDMO headquartered in North Augusta, South Carolina (US), with facilities in US and Shanghai. Financial terms of the deal were not disclosed.
The acquisition adds differentiated peptide manufacturing capabilities to CordenPharma’s existing Peptides Platform, including advanced linear and fragment-based peptide approaches supported by flexible solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid synthesis, complementing CordenPharma’s proprietary Tag-Assisted Peptide Synthesis (TAPS). AmbioPharm employs approximately 400 people across its two sites.
The North Augusta facility will serve as CordenPharma’s second US peptide manufacturing site, adding capacity focused on purification and lyophilisation of peptide APIs, complementing its existing Colorado facility. The Shanghai campus will support clinical and commercial global peptide supply with upstream capacity across SPPS, LPPS and hybrid synthesis. Taken together, the acquisition extends CordenPharma’s global Peptides Platform across three continents.
Dr. Michael Quirmbach, President and CEO of CordenPharma Group, said the deal advances the company’s strategic objective to serve as a leading peptide manufacturing partner, noting that customers increasingly value CDMOs offering both upstream scientific expertise and downstream manufacturing scale with geographic flexibility. “AmbioPharm’s capabilities perfectly complement our existing peptide expertise, helping us to broaden the ways we support customers from development to commercialisation,” he added.
As part of the transaction, AmbioPharm’s shareholders will reinvest into the combined business. The deal remains subject to customary closing conditions. CordenPharma has been owned by pan-European private equity firm Astorg since 2022.
